Bone scintigraphy imaging of cardiac amyloidosis by Kuria, Issa Menge et al.
eCommons@AKU 
Imaging & Diagnostic Radiology, East Africa Medical College, East Africa 
9-2019 
Bone scintigraphy imaging of cardiac amyloidosis 
Issa Menge Kuria 
Samuel Gitau 
Khalid Makhdomi 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_imaging_diagn_radiol 
 Part of the Radiology Commons 
314 © 2019 World Journal of Nuclear Medicine | Published by Wolters Kluwer - Medknow
Case Report
ABSTRACT
Transthyretin‑related cardiac amyloidosis (ATTR) amyloidosis is an aggressive, rapidly progressive, and fatal disease, for which several 
promising therapies are in development. This condition is frequently underdiagnosed because of the limited specificity of echocardiography 
and the traditional requirement for histological diagnosis. It is well known that 99mtechnetium‑labeled bone scan radiotracers can localize in the 
myocardial amyloid deposits, but the use of this imaging modality to differentiate between the two subtypes has only lately been revisited. We 
report a case of a 76‑year‑old man with a clinical diagnosis of amyloidosis who underwent a bone scan that had features of ATTR amyloidosis. 
To the best of our knowledge, this is the first case report in Sub‑Saharan Africa.
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INTRODUCTION
Cardiac amyloidosis is a rare cause of rapidly progressive, 
restrictive cardiomyopathy and congestive heart 
failure.[1] It is mostly difficult to diagnose and almost 
always associated with poor prognosis. There are two 
main subtypes of cardiac amyloidosis: transthyretin‑related 
cardiac amyloidosis (ATTR) and cardiac light‑chain (AL) 
amyloidosis.[2,3] Differentiating the two is important for 
both prognosis and management, and this was only possible 
through invasive biopsy procedures. Recently, however, a 
few published cases have shown that bone scintigraphy is 
able to reliably distinguish between the two.[4] In this case, 
we report findings on the bone scan that supported the 
diagnosis of ATTR cardiac amyloidosis.
CASE REPORT
A 76‑year‑old male who had clinical suspicion for 
cardiac amyloidosis was referred to our department 
for bone scintigraphy to try and differentiate between 
the two main clinical subtypes. Planar whole‑body 
images were performed in the anterior and posterior 
projections 4 h after intravenous administration of 
718 MBq (19.4 mCi) of 99mtechnetium (99mTc) methylene 
diphosphonate (99mTc MDP).
The bone scan images [Figure 1] demonstrated diffusely 
increased tracer uptake in the heart and attenuated tracer 
uptake throughout the bones. Increased tracer uptake was 
also seen in the soft tissues of deltoid, gluteal, and abdominal 
walls. No other site of abnormal tracer concentration was seen.
Figure 1a and b shows the planar whole‑body bone scan 
in the anterior projection [Figure 1a] and a zoomed 
image [Figure 1b] demonstrating moderately intense cardiac 
uptake with soft tissue uptake involving the shoulders, chest, 
abdominal walls, and hips. Skeletal tracer uptake appears 
mildly suppressed.
DISCUSSION
Cardiac amyloidosis is a rare cause of rapidly progressive, 
restrictive cardiomyopathy and congestive heart failure.[1] It 
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is mostly difficult to diagnose and almost always associated 
with poor prognosis. There are two main subtypes of cardiac 
amyloidosis: transthyretin‑related cardiac amyloidosis (ATTR) 
and cardiac light‑chain (AL) amyloidosis.[2,3] ATTR amyloidosis 
may be acquired and hereditary that is either associated with 
variants in the transthyretin gene or associated with wild‑type 
transthyretin (also called senile systemic amyloidosis).
Cardiac AL amyloidosis is more rapidly progressive than 
the ATTR type where the former is associated with >50% 
mortality within 6 months after the diagnosis while the 
ATTR subtype has a favorable prognosis of 98% 2‑year 
survival.[5,6] The treatment options for the two subtypes 
are also different with AL subtype likely to benefit from 
cytotoxic chemotherapy,[7] while more novel therapies are 
used for ATTR including inotersen, which was recently 
approved by the FDA for the treatment of hereditary ATTR 
amyloidosis polyneuropathy.[8] Differentiating the type of 
cardiac amyloidosis (ATTR or AL) is thus vital in guiding 
patient management.
Because cardiac amyloidosis has nonspecific clinical 
symptoms as well as nonspecific electrocardiogram and 
echocardiographic findings,[9] it remains a diagnostic 
challenge and is often underdiagnosed. The gold standard for 
the diagnosis of amyloidosis is through biopsy of a clinically 
affected organ, with Congo red histology demonstrating 
green birefringence. However, when amyloidosis is 
clinically suspected, biopsy of the salivary glands, rectum, 
or subcutaneous fat usually yields the diagnosis in 60%–80% 
of patients with AL amyloidosis.[10] Unfortunately, a much 
lower yield is observed in patients with ATTR amyloidosis 
that requires for endomyocardial biopsy (EMB) to confirm 
the diagnosis.[11] EMB has its own risks including myocardial 
perforation, tamponade, and fatality. It also requires expertise 
and this can introduce diagnostic delays.[12]
Cardiac magnetic resonance imaging (CMR) is a more 
discriminating method for cardiac amyloidosis but does not 
differentiate types of amyloidosis and cannot be performed 
in the presence of implanted devices.[13] All of these factors 
contribute to under diagnosis, which is crucial given the 
poor prognosis of AL and ATTR cardiac amyloidosis and 
the increasing availability of novel therapies for both 
subtypes.[14,15]
Radionuclide bone scans with 99mTc‑labeled bisphosphonates 
have been anecdotally reported to localize cardiac amyloid 
deposits, although the molecular basis for this remains 
unknown.[16] The cardiac uptake on the planar images is 
visually scored using the Perugini grading system.[17] Briefly, 
it is categorized as follows: Grade 0 – no cardiac uptake 
and normal bone uptake; Grade 1 – cardiac uptake which is 
less intense than the bone signal; Grade 2 – cardiac uptake 
with intensity similar or greater than bone signal; and 
Grade 3 – cardiac uptake with much attenuated or absent 
bone signal. An uptake of Grade 2 and above is considered 
significant.[17] A systematic evaluation of bone scans of 
857 patients with histologically proven amyloid revealed 
that cardiac ATTR amyloidosis can be reliably diagnosed in 
the absence of histology provided that all of the following 
criteria are met: heart failure with an echocardiogram or CMR 
that is consistent with or suggestive of amyloidosis, Grade 2 
or 3 cardiac uptake on a radionuclide scan with 99mTc‑labeled 
3,3‑diphosphono‑1,2‑propanodicarboxylic acid (99mTc‑DPD), 
99mTc‑labeled pyrophosphate (99mTc‑PYP), or 99mTc‑labeled 
hydroxymethylene diphosphonate, and absence of a 
detectable monoclonal protein.[4] More recently, studies[18,19] 
have shown that 99mTc‑labeled MDP can also preferentially 
bind to ATTR as similar to 99mTc PYP and 99mTc DPD.
Given that 99mTc‑MDP is more readily available than DPD 
or PYP and already in use for routine bone scans, it would 
provide a more feasible option in this diagnostic algorithm. 
Unfortunately, cardiac localization of radiotracers also occurs 
in a small proportion of patients with AL amyloidosis, and 
although it is usually low grade, it can confound distinguishing 
between cardiac AL and ATTR subtypes.[20] A recent study by 
Hutt et al.[21] that had a cohort of 321 patients with suspected 
cardiac amyloidosis that used 99mTc DPD as the radiotracer 
Figure 1: (a and b) shows the planar whole‑body bone scan in the anterior 
projection (a) and a zoomed image (b) demonstrating moderately intense 
cardiac uptake with  soft tissue uptake  involving  the  shoulders,  chest, 
abdominal walls, and hips. Skeletal tracer uptake appears mildly suppressed
ba
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demonstrated that in addition to the intense cardiac uptake 
in patients with ATTR, these patients also demonstrated 
extensive soft tissue uptake in the deltoid, abdominal wall, 
and gluteal muscles that was not seen in the AL amyloidosis 
patients. They concluded that the soft tissue uptake in those 
sites is specific to ATTR. Our patient demonstrated intense 
cardiac uptake in addition to soft tissue uptake in the deltoid, 
gluteal, and abdominal wall muscles that is relatively specific 
to ATTR amyloidosis.
CONCLUSION
Several studies[4,20] have concluded that cardiac transthyretin 
amyloidosis can be reliably diagnosed in the absence of 
histology provided that all of the following criteria are 
met: heart failure with an echocardiogram or CMR that 
is consistent with or suggestive of amyloidosis, intense 
cardiac uptake on a 99mTc labeled bisphosphonate bone scan, 
no detectable monoclonal protein in serum with normal 
serum‑free light chains. AL amyloidosis is unlikely in any 
patient satisfying all the above criteria. Invasive EMB can 
therefore be avoided in elderly patients who satisfy these 
criteria. In this regard, 
99mTc‑labeled bisphosphonate bone 
scans serve an integral role in the workup of patients with 
suspected cardiac amyloidosis. Histological confirmation and 
typing of amyloid should be sought in all cases of suspected 
cardiac amyloidosis in whom these criteria are not met.
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